News
Novo Nordisk cuts forecasts as Ozempic and Wegovy sales hit by US copycat versions
Novo Nordisk has slashed its full-year revenue and profit forecasts for the first time since launching its blockbuster weight-loss drug Wegovy, as unauthorised compounded versions of its GLP-1 drugs eat into sales — particularly in the United States,
Novo Nordisk (NVO) won a key case Thursday to stop some compounding ... which are supposed to halt selling compounded ...
About a dozen lawsuits, citing 2024 studies, allege Ozempic causes a rare eye disorder that leads to irreversible blindness. ...
1don MSN
The company’s blockbuster drugs helped it beat Wall Street’s expectations—while WeightWatchers declares bankruptcy.
A grandma of 11 and a New Jersey man have joined the growing chorus of users of the wildly popular weight-loss drugs Ozempic ...
1d
Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...
Novo Nordisk faces a suit claiming it failed to warn users of Ozempic of the danger of blindness. The suit is brought by a ...
Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug ...
The U.S. Food and Drug Administration (FDA) and drug manufacturer Novo Nordisk are warning consumers about “counterfeit” ...
With more and more people signing up for weight loss drugs, the potential side effects are starting to attract attention.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback